candida antigen
PreclinicalBiologic
candida antigen is one of 4 biologic programs targeting Common Wart. It is currently in Preclinical.
1
Indications
5
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Common Wart
#DrugCompanyPhaseTrials
1Vistide
GileadApproved
Trexall
Jazz PharmaceuticalsPreclinical
candida antigen
UUniversity of Arkansas
Preclinical
CRYOTHERAPY
AAssistance Publique - Hôpitaux de Paris
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cutaneous Warts1 trial
Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts
Unknown status·—·Phase 3·NCT03158168·70 enrolled
Papilloma1 trial
Genital Warts1 trial
Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts
Unknown status·—·Phase 3·NCT03853785·45 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for candida antigen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Arkansas